← All trials
NCT05347199
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2022
- Primary completion
- Oct 31, 2023
- Completion date
- Oct 31, 2023
- First posted
- Apr 26, 2022
- Last posted
- May 2, 2022
- Enrollment
- 120
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medical School BerlinLead sponsor
- Boehringer IngelheimCollaborator
- Humboldt UniversityCollaborator
- Humboldt UniversityOverall official - principal investigator
- Medical School BerlinSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.